



Tricare has expanded CGM coverage for all insulin users¹



The patient has a diagnosis of T1 diabetes or T2 diabetes mellitus, and one of the following situations applies²:

Patient is using basal and prandial insulin injections,

OR

Patient is using a continuous subcutaneous insulin infusion (ie, insulin pump),

OR

Patient has Type 2 diabetes mellitus and is receiving insulin therapy and has a history of severe hypoglycemia episodes requiring medical intervention. The patient has a diagnosis of diabetes and is currently being **treated with insulin**¹.

Automated PA: The patient has filled a prescription for insulin during the **previous** 180 days^{*1}.




DHA = Defense Health Agency, PA=Prior Authorization

^{*} If automated criteria are not met, coverage is manually approved for FreeStyle Libre 2 systems and FreeStyle Libre 3 systems if all criteria are met.

^{1.} Department of Defense Pharmacy and Therapeutics Committee Recommendations from the February 2024 meeting, <u>https://health.mil/Reference-Center/Meeting-References/2024/03/27/UF-BAP-Background-Document-April-3-2024-time-zone-edited</u>. Accessed May 9, 2024. **2.** Department of Defense Pharmacy and Therapeutics Committee Recommendations from the November 2022 Meeting Information for the Uniform Formulary Beneficiary Advisory Panel, <u>https://www.health.mil/Reference-Center/Meeting-References/2022/12/16/BAP-Background-Document-for-the-Nov-2022-PT-Meeting</u>. Accessed May 17, 2024.





Abbott provides this information as a courtesy and does not guarantee payment or coverage.

T1D: type 1 diabetes; T2D: type 2 diabetes; MDI: multiple daily injections

* 2016-2018 data. **†** 2012–2015 data. **‡** Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products.

§ Data from this study was collected with the US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre system 14 day with real-time glucose alarms. Therefore the study data is applicable to both products. **||** Data from this study was collected with the US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products. **¶** Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products. **¶** Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore the study is applicable to both products. **#** Baseline A1c between 8% and 12%.

 Foster, N. Diabetes Tech Ther (2019). <u>https://doi.org/10.1089/dia.2018.0384</u>.
Brixner, D. Clinical Ther (2019). <u>https://doi.org/10.1016/j.</u> <u>clinthera.2018.12.014</u>.
Tyndall, V. Diabetologia (2019): <u>https://doi.org/10.1007/s00125-019-4894-1</u>.
Kroger, J. Diabetes Ther (2020): <u>https://doi.org/10.1007/s13300-019-00741-9</u>.
Carlson, A. *BMJ Open Diabetes Res Care* (2022). <u>https://doi.org/10.1136/</u> <u>bmjdrc-2021-002590</u>.
Wright, E. Diabetes Spectr (2021). <u>https://doi.org/10.2337/ds20-0069</u>.

Important Safety Information

FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or https://www.FreeStyle.abbott/us-en/safety-information.html for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. © 2024 Abbott. ADC-92237 v2.0

